Wells Fargo & Company Has Lowered Expectations for NovoCure (NASDAQ:NVCR) Stock Price

Key Points

• Wells Fargo cut NovoCure’s price target from $20 to $15 while maintaining an “equal weight” rating, implying roughly 16.4% upside from the stock’s $12.89 price. The broader analyst consensus remains “Hold,” with a $20.80 target.
• NovoCure’s third-quarter results exceeded expectations: revenue rose 15.7% year over year to $193.4 million, while its $0.09 per-share loss was narrower than anticipated. Despite the earnings beat and raised guidance, the company remains unprofitable.
• Slower Optune Pax adoption, partly attributed to competing pancreatic-cancer treatment daraxonrasib, is weighing on investor sentiment. Shares fell 1.7%, and the stock remains well below its 52-week high of $21.45.

NovoCure (NASDAQ:NVCR - Get Free Report) had its price objective dropped by stock analysts at Wells Fargo & Company from $20.00 to $15.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an "equal weight" rating on the medical equipment provider's stock. Wells Fargo & Company's price objective suggests a potential upside of 16.37% from the stock's current price.

A number of other equities analysts also recently weighed in on NVCR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NovoCure in a research report on Thursday, August 27th. HC Wainwright set a $32.00 price objective on shares of NovoCure in a research report on Friday, July 24th. Wedbush raised their target price on NovoCure from $18.00 to $20.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. JPMorgan Chase & Co. began coverage on shares of NovoCure in a report on Monday, July 13th. They set a "neutral" rating and a $17.00 price objective for the company. Finally, Zacks Research upgraded shares of NovoCure from a "strong sell" rating to a "hold" rating in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $20.80.

NovoCure Trading Down 1.7%

Shares of NVCR stock traded down $0.22 during mid-day trading on Friday, reaching $12.89. 631,485 shares of the stock traded hands, compared to its average volume of 1,678,152. The stock's fifty day simple moving average is $15.88 and its two-hundred day simple moving average is $14.79. NovoCure has a 1-year low of $9.82 and a 1-year high of $21.45. The company has a quick ratio of 2.70, a current ratio of 2.89 and a debt-to-equity ratio of 0.58. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -9.93 and a beta of 0.99.

NovoCure (NASDAQ:NVCR - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.14. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.00%. The company had revenue of $193.40 million for the quarter, compared to analyst estimates of $182.28 million. During the same quarter in the previous year, the business earned ($0.33) earnings per share. NovoCure's revenue was up 15.7% compared to the same quarter last year. On average, research analysts anticipate that NovoCure will post -1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quantinno Capital Management LP raised its position in shares of NovoCure by 23.7% in the first quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider's stock worth $27,112,000 after buying an additional 477,128 shares in the last quarter. Renaissance Technologies LLC boosted its position in NovoCure by 11.8% during the first quarter. Renaissance Technologies LLC now owns 1,551,554 shares of the medical equipment provider's stock valued at $16,912,000 after buying an additional 163,800 shares during the period. Dimensional Fund Advisors LP lifted its position in NovoCure by 27.6% in the first quarter. Dimensional Fund Advisors LP now owns 960,056 shares of the medical equipment provider's stock valued at $10,462,000 after purchasing an additional 207,913 shares during the last quarter. Allianz Asset Management GmbH bought a new stake in NovoCure in the 2nd quarter worth $2,248,000. Finally, California State Teachers Retirement System boosted its holdings in shares of NovoCure by 43.6% during the first quarter. California State Teachers Retirement System now owns 142,561 shares of the medical equipment provider's stock worth $1,554,000 after purchasing an additional 43,257 shares during the period. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported third-quarter revenue of $193.4 million, up 15.7% year over year and above the $182.3 million analyst consensus. The company’s adjusted loss of $0.09 per share also beat expectations, while the loss narrowed from $0.33 per share a year earlier. NovoCure Q3 earnings report
• Positive Sentiment: The company raised its 2026 financial guidance, signaling confidence in ongoing revenue growth and execution. The improved outlook was a favorable element of the earnings release, although investors appear focused on the pace of commercial adoption. NovoCure raises 2026 guidance
• Positive Sentiment: NovoCure entered a clinical-trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy alongside VS-7375 in pancreatic cancer. The partnership could expand the company’s clinical pipeline and provide another potential application for its technology, though it remains an early-stage opportunity. NovoCure and Verastem collaboration
• Negative Sentiment: Management said adoption of Optune Pax has been slower because of Revolution Medicines’ daraxonrasib, raising concerns that competing pancreatic-cancer treatment options could delay or limit uptake. Wedbush characterized the treatment as a potential market disruption rather than direct competition, but the issue appears to have overshadowed the earnings beat. Optune Pax adoption and daraxonrasib

About NovoCure

NovoCure Ltd. NASDAQ: NVCR is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company's principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.